Lupus is a long term condition that can cause inflammation to the joints, skin and other organs.
It is a systemic autoimmune disease that has no known cure, and occurs when your body’s immune system attacks its own tissues and organs.
The organs that can come under attack include kidneys, brain, heart and lungs. Blood cells can also be affected. In its mildest form, lupus simply causes inflammation and tiredness, and can be managed. At its most severe, it can be life threatening.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.